Money is needed to do the research we have done and will perform in the (near) future. Happily we can anounce and thank different companies; funding organisations and parent organisations for their funding for the exon skipping group.

Duchenne Parent Project

* Improving the 2’-O-methyl phosphorothioate induced exon skipping for Duchenne through chemical modification and/or a combination with added components: summary of the project (in Dutch)
* Clarifying the role and therapeutic effect of myostatin/ TGF-β receptors: summary of the project (in Dutch)
* Preparing for double exon skipping therapy
* Validating a mouse model to test human specific antisense oligonucleotides
* In-depth characterisation of brain pathology in mice lacking one or multiple brain dystrophin isoforms

Prinses Beatrix Spierfonds

* Improving exon skipping therapy for Duchenne
* mRNA as key to improve possible Duchenne therapies
* Double therapy for Duchenne muscular dystrophy: research ended


* Biomarkers in DMD: from the discovery to the development toward clinical application and translation in other NMDs (ENMC WS 204)
* Antisense therapy for several major rare diseases


* Cross-sectional study to assess detailed natural disease history of limb girdle muscular dystrophy mouse models